Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Consensus price target: $1,280.00 (+91986.33% upside from $1.39)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $1.24B |
| 2024 | $0 | — | $-15.01M |
| 2023 | $0 | — | $-29.07M |
Stock data for ENLV: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics